Mother Calls for Funded Wegovy to Treat Antipsychotic Weight Gain

“He no longer raids the fridge at night, he looks great and he takes the dog for long walks every day,” his mother told RNZ.

“Best of all, his social confidence has improved and his sadness has lifted. The drug has given him back his hope and self respect.”

That transformation came at a price the family cannot sustain: roughly $500 a month for Wegovy, covered for a single year by a family friend. The 47-year-old West Coast man, who has lived with schizophrenia for more than two decades, dropped from 120 kilograms to 98 kilograms on the GLP-1 agonist.

His mother, whom RNZ agreed not to name to protect the family’s privacy, is now calling for Pharmac to fund the medication specifically for people who gain weight on antipsychotics — a population she says is being left behind.

Her son’s weight gain began shortly after he started olanzapine in his twenties, following a psychotic episode that led to hospitalisation.

The drug stabilised his mental health, but the metabolic side effects were swift and severe: more than 20 kilograms added, gallbladder removal, and a nightly cycle of compulsive eating that eroded his dignity. When the year of funded treatment ends, she warned RNZ, “Regaining the weight would plunge him into despair.”

On Wegovy, the man's weight had dropped from 120kg to 98kg. Photo / RNZ
Photo: nzherald.co.nz

Pharmac told RNZ it has not received an application for Wegovy specifically to treat antipsychotic-induced weight gain. That gap — between a recognised clinical need and a formal funding pathway — sits at the centre of a widening debate over how New Zealand’s health system manages the physical health of people with serious mental illness.

“The medications actually can increase appetite, often within weeks. So it’s not that people who gain weight on these medications have failed in any way. It’s a known biological effect, a very well recognised side effect,”

Professor Susanna Every-Palmer, psychiatrist and head of the Department of Psychological Medicine at the University of Otago in Wellington, told RNZ.

Olanzapine and clozapine carry the highest risk of metabolic disturbance, according to clinical summaries cited by WebMD and referenced in the RNZ reporting. The consequences cascade: people with schizophrenia die well over a decade earlier than the general population, mostly from heart disease and diabetes, Every-Palmer noted.

Yet access to GLP-1 medicines in New Zealand remains tight, she said. “And that is something that we as a health system, I think, should be investing in.”

Dan Goodwin, community support manager at Changing Minds, a national mental health not-for-profit, told RNZ that weight gain is one of the primary reasons people stop taking psychiatric medication altogether.

“On top of the experiences that the anti-psychotics might be treating […] now you also have a changing physical body as well, which might be causing you distress or it might be causing its own sense of shame due to stigma and discrimination around weight gain and body size.”

Because clinical priority is almost always assigned to the primary mental distress, the metabolic fallout is rarely treated as urgent, compounding the shame, Goodwin said.

Goodwin predicts the pressure will only grow. “It’s going to become a more common request as those drugs kind of get developed and grow,” he told RNZ. For the West Coast family, the timeline is measured not in policy cycles but in the months remaining on a gift they cannot replace.